Skip to content
    Clinical Trials

    ctDNA-Guided Cetuximab and Irinotecan Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer

    Wang et alClinical and Translational Medicine

    ctDNA-Guided Cetuximab and Irinotecan Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
    In patients with metastatic colorectal cancer (mCRC), mutant subclones driving secondary resistance to anti-EGFR therapy can decay following drug cessation, creating potential opportunities for treatment rechallenge. A single-arm, phase II nonrandomised trial (NCT04224415) evaluated the efficacy and safety of liquid biopsy-guided therapy, specifically using circulating tumour DNA (ctDNA) to select patients for rechallenge with cetuximab plus irinotecan.
    Eligible participants had histologically confirmed RAS/BRAF wild-type (WT) mCRC at diagnosis, prior clinical benefit from first-line cetuximab-based therapy, subsequent disease progression during or within 3 months of cetuximab, disease progression following at least one additional line of systemic therapy, a cetuximab washout period of at least 4 months, and ctDNA confirmation of RAS/BRAF WT status immediately prior to rechallenge. Patients received intravenous cetuximab (500 mg/m²) and irinotecan (180 mg/m²) in 2-week cycles. The primary endpoint was objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs).
    Among 36 enrolled patients, partial responses occurred in 6 patients (16.7%), stable disease was achieved in 10 (27.8%), and progressive disease was documented in 16 (44.4%), while 4 patients were unevaluable due to early loss to follow-up. The confirmed ORR was 16.7% (95% CI: 7.9–31.9) and the disease control rate was 44.4% (95% CI: 29.5–60.4). Median PFS was 3.9 months (95% CI: 3.1–4.7) and median OS reached 13.0 months (95% CI: 8.1–17.9). On multivariate Cox regression analysis, a longer screening time interval (STI) independently predicted improved PFS (HR = 0.93 per additional month; 95% CI: 0.88–0.99). High-grade (grade 3–4) TRAEs were infrequent and clinically manageable. The findings suggest ctDNA profiling and interval duration can inform patient selection for anti-EGFR rechallenge in mCRC.

    Key Takeaways

    • ctDNA-guided rechallenge with cetuximab plus irinotecan achieved an objective response rate of 16.7% (95% CI: 7.9–31.9) and a disease control rate of 44.4% (95% CI: 29.5–60.4) in patients with RAS/BRAF wild-type metastatic colorectal cancer.
    • Median progression-free survival was 3.9 months (95% CI: 3.1–4.7) and median overall survival reached 13.0 months (95% CI: 8.1–17.9), with each additional month of screening time interval independently reducing the risk of progression (HR = 0.93; 95% CI: 0.88–0.99).
    • Grade 3 to 4 treatment-related adverse events were uncommon and clinically manageable during the two-week cetuximab and irinotecan rechallenge regimen.
    Read the original sourceClinical and Translational Medicine